Article info

Protocol
Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO

Authors

  1. Correspondence to Drs Michelle V Dietz; m.dietz{at}erasmusmc.nl
View Full Text

Citation

van Kooten JP, Dietz MV, Guchelaar NAD, et al
Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO

Publication history

  • Received March 16, 2022
  • Accepted June 8, 2022
  • First published June 22, 2022.
Online issue publication 
June 22, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.